Preventing the Influenza virus

Plan-les-Ouates, Geneva, Switzerland – Jan 2, 2008

Viroblock has started the first series of experiments to validate its antiviral approach against Influenza virus. Initial in vitro assays will be followed by a series of animal testing using the ferret model. These proof-of-principle experiments aim at demonstrating the ability of Viroblock’s products to prevent the natural transmission of human Influenza virus.

This will be done in UK in partnership with Retroscreen Virology Ltd, a Europe's leading contract Virology research company.

About Retroscreen Virology Ltd.
Retroscreen Virology Limited is an independent research virology company affiliated with the University of London. Retroscreen Virology Ltd was founded in 1989 and has grown to be one of the most innovative virological research and clinical trials companies in its field.

Retroscreen specializes in developing anti-viral compounds and vaccines, and has worked with many pharmaceutical companies to assist them in developing products that now help to fight viral disease worldwide. It conducted the first human influenza A and B virus challenge studies in a quarantine unit in the United Kingdom in 20 years, developed and produced pilot batches of an HIV vaccine, and developed and cultivated the SARS virus in its upgraded containment level III laboratory.

Additional information is available on the company's website at www.retroscreen.com

For more information:
Thierry Pelet, CEO
+41 22 884-8344